Location History:
- MI, US (1978)
- Kalamazoo, MI (US) (1976 - 1981)
Company Filing History:
Years Active: 1976-1981
Title: The Innovative Contributions of Ladislav J Hanka
Introduction
Ladislav J Hanka is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of microbiology and antibiotic development. With a total of 5 patents, Hanka's work focuses on creating new antibiotics that combat various bacterial infections.
Latest Patents
Hanka's latest patents include a biologically pure culture of Paecilomyces abruptus, which produces a new antibiotic known as U-53,946. This antibiotic is effective against Gram-positive bacteria such as Sarcina lutea, Staphylococcus aureus, Bacillus subtilis, Mycobacterium avium, and Streptococcus pyogenes, as well as the yeast Saccharomyces pastorianus. His research indicates that this antibiotic can be utilized in various environments to eradicate or control these microorganisms. Another significant patent is for a novel antibiotic, CC-1065, which is produced through controlled fermentation using the microorganism Streptomyces zelensis. This antibiotic is active against both Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes, Escherichia coli, and Salmonella pullorum. The versatility of CC-1065 allows it to be used in diverse settings to manage bacterial infections.
Career Highlights
Hanka is currently associated with The Upjohn Company, where he continues to innovate in the field of antibiotic research. His work has been instrumental in advancing the development of effective treatments for bacterial infections.
Collaborations
Hanka has collaborated with notable coworkers such as Paul F Wiley and David G Martin, contributing to the success of his research endeavors.
Conclusion
Ladislav J Hanka's contributions to antibiotic development highlight his innovative spirit and dedication to improving public health. His patents reflect a commitment to addressing bacterial infections through novel solutions.